The same oral bacteria that cause cavities might be colonizing your gut and triggering Parkinson’s disease, according to new research that traces a startling pathway from dental hygiene to neurodegeneration.
Korean scientists have identified how Streptococcus mutans, the notorious tooth-decay bacterium, produces a metabolite that travels from the intestines to the brain, where it systematically destroys dopamine-producing neurons. The findings, published in Nature Communications, reveal elevated levels of both the bacteria and its toxic byproduct in Parkinson’s patients.
From Gut Colonization to Brain Destruction
The research team, led by Professor Ara Koh at POSTECH, analyzed gut microbiome data from 491 Parkinson’s patients and found significantly higher levels of S. mutans compared to healthy controls. More concerning was the discovery that these bacteria carry an enzyme called urocanate reductase (UrdA) that produces imidazole propionate, a metabolite that can cross the blood-brain barrier.
“Our study provides a mechanistic understanding of how oral microbes in the gut can influence the brain and contribute to the development of Parkinson’s disease.”
When researchers introduced S. mutans into germ-free mice, the animals developed classic Parkinson’s symptoms within weeks: tremors, motor dysfunction, and the characteristic loss of dopaminergic neurons in the substantia nigra. Brain tissue analysis showed elevated levels of imidazole propionate, confirming the metabolite’s ability to penetrate neural tissue.
The mechanism centers on mTORC1, a cellular signaling complex that becomes hyperactivated by imidazole propionate. This activation triggers a cascade of neuronal death specifically targeting dopamine-producing cells. When researchers blocked mTORC1 with the inhibitor rapamycin, they prevented both neurodegeneration and motor symptoms, even as bacterial colonization continued.
Oral Health Meets Neurological Disease
The study’s most unsettling implication involves the journey these bacteria make from mouth to brain. S. mutans typically resides in dental plaque, but the research demonstrates these microbes can establish colonies throughout the digestive tract, particularly in the distal gut regions like the ileum and colon.
Once established, the bacteria begin producing imidazole propionate, which enters systemic circulation and accumulates in brain tissue. The metabolite showed particular toxicity toward midbrain dopaminergic neurons while sparing other brain regions, explaining why the resulting symptoms specifically mirror Parkinson’s pathology rather than general neurodegeneration.
Plasma analysis of 65 Parkinson’s patients revealed significantly elevated imidazole propionate levels compared to age-matched controls, suggesting this bacterial pathway may contribute to human disease progression. The patients averaged 9.5 years of disease duration, indicating the metabolite remains elevated throughout the condition’s course.
The research extends beyond simple bacterial colonization. When scientists engineered E. coli to express the S. mutans UrdA enzyme, these modified bacteria produced identical neurological damage, confirming that the enzyme itself drives pathology regardless of the bacterial host.
Testing direct metabolite toxicity, researchers injected imidazole propionate directly into mouse brains and observed rapid dopaminergic neuron death within three days. Systemic administration over three weeks produced similar results, demonstrating the compound’s potent neurotoxic effects through multiple delivery routes.
The study also examined interactions with alpha-synuclein, the misfolded protein that accumulates in Parkinson’s brain lesions. Imidazole propionate accelerated alpha-synuclein aggregation and worsened existing pathology in mouse models, suggesting the bacterial metabolite may both initiate disease and accelerate its progression.
Current therapeutic approaches for Parkinson’s focus primarily on symptom management through dopamine replacement. This research points toward prevention strategies targeting the gut microbiome before neurological damage occurs. The identification of UrdA as a key pathogenic enzyme suggests potential drug targets for blocking imidazole propionate production.
The findings raise questions about antibiotic use and oral health practices in disease prevention. While the research doesn’t establish definitive causation in human disease, it provides a mechanistic framework for understanding how gut bacteria might influence neurodegeneration through metabolite production.
The mTORC1 pathway’s central role offers additional therapeutic possibilities. Rapamycin and related compounds that inhibit this signaling complex showed protective effects in animal models, though their long-term safety and efficacy in humans would require extensive clinical testing.
This bacterial pathway to neurodegeneration represents a paradigm shift in understanding Parkinson’s etiology. Rather than viewing the disease as primarily genetic or environmental, the research suggests certain cases may result from microbial metabolites systematically damaging brain tissue over extended periods.
The study’s implications extend beyond Parkinson’s to broader questions about microbiome influences on neurological health. As researchers continue mapping bacterial metabolites and their effects on neural tissue, oral hygiene practices may prove more crucial to brain health than previously recognized.
Nature Communications: 10.1038/s41467-025-63473-4
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.